Parma, 22 September 2026 – Maria Paola Chiesi, Chair of the Board of Chiesi Group, has joined the Chairs of several leading healthcare companies in signing an open letter urging policymakers to consider investment in health and innovation as a strategic priority for Europe's future competitiveness,…
Chiesi Farmaceutici has announced a strategic partnership with Abdi İbrahim to implement a new operating model for Chiesi’s business in Türkiye. Effective 1 October 2026, the partnership will combine Chiesi's global scientific expertise, innovative portfolio and high-quality standards with Abdi…
Following Chiesi's evaluation of the seralutinib development program and the PROSERA Phase 3 study results, Chiesi and Gossamer Bio have agreed to terminate their Collaboration and License Agreement related to the development and commercialization of seralutinib for the treatment of patients with…
Chiesi today announces MHRA approval in the UK of Clenil Modulite (beclometasone; 100mcg and 200mcg) formulated with a non-PFAS, low-GWP, next generation propellant (HFA-152a). These are the first pMDIs to use HFA-152a worldwide, with the UK being the first country to approve these products.…
Chiesi Group and Oak Hill Bio Holdings have announced the completion of patient enrollment in the Phase 2b FOOTPRINTS study evaluating OHB-607 for the prevention of bronchopulmonary dysplasia (BPD), a leading cause of chronic lung disease in premature infants for which there are currently no…
Parma, Italy – 18 May 2026 Chiesi announces that the U.S. Food and Drug Administration (FDA) has approved its single-inhaler triple therapy (beclomethasone dipropionate/formoterol fumarate/glycopyrrolate; BDP/FF/G ) for the maintenance treatment of asthma in adults. The approval was supported by two…
Gossamer Bio released today the topline results from the Phase 3 PROSERA clinical study evaluating seralutinib, an investigational inhaled therapy, in people living with pulmonary arterial hypertension (PAH). Gossamer Bio and Chiesi are jointly developing seralutinib under a global collaboration…
Parma, Italy – 18 December 2025 Chiesi announces the submission of the Carbon Minimal pressurised metered-dose inhaler (pMDI) containing beclometasone in 100 mcg and 200 mcg strengths to the UK Medicines and Healthcare products Regulatory Agency (MHRA) on 5 th December 2025. This submission is part…
Chiesi Group today announced its decision to conclude all clinical trials for the tanimilast program in Chronic Obstructive Pulmonary Disease (COPD) and asthma. This decision follows the full analysis of the Phase 3 PILASTER Main Cohort study in COPD, which did not meet its primary and key secondary…
You are leaving the Chiesi Corp site to access another Chiesi site. Regulatory constraints and medical practices, as well as the information published on the site you are about to visit, may change from one country to another and may not comply with current Italian legislation on the subject.
You are about to leave our website and access an external site. By continuing, you agree to leave our site.
